21 May 2019
The 2019 State of the Discovery Nation report offers a revealing insight into the current status of the drug discovery community in the UK, clearly indicating that companies are beginning to leverage technological advances to improve the drug discovery pipeline. The report is compiled from responses to survey questionnaires sent out to small and medium-sized enterprises (SMEs) in the UK by the BioIndustry Association in collaboration with the Medicines Discovery Catapult (MDC) to create a snapshot of the current situation. This is the second report of its kind and is focused on two key areas: artificial intelligence (AI) for drug discovery and complex preclinical cell models, or CCM.
SMEs are crucial in the drug discovery process, in terms of employment and the innovation that they bring to the process. In terms of clinical areas, cancer came out as the strongest, with almost half the SMEs analysed focusing on oncology and over 38 percent of drug assets in development aimed at this area. [Read more…]